Main comedications associated with major bleeding during anticoagulant therapy with coumarins

European Journal of Clinical Pharmacology

Volumn 61, Issue 5-6, 2005, Pages 439-444

  Penning Van Beest, Fernie ^a   Erkens, Joëlle ^a   Peterson, Karl Uwe ^b   Koelz, Hans Rudolf ^c   Herings, Ron ^a,d  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c TRIEMLI HOSPITAL   (Switzerland)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; COUMARIN; DICLOFENAC; DOXYCYCLINE; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OMEPRAZOLE; PHENPROCOUMON; SALICYLIC ACID; TRAMADOL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ACENOCOUMAROL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; COHORT STUDIES; COUMARINS; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PHENPROCOUMON; RETROSPECTIVE STUDIES; SALICYLATES;

EID: 27644443716     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0947-0     Document Type: Article

References (23)

1. Caron J, Libersa C, Thomas C (1996) Drugs affecting blood clotting, fibrinolysis, and hemostasis. In: Dukes MNG (ed) Meyler's side effects of drugs: an encyclopedia of adverse reactions and interactions, 13th edn. Elsevier Science, Amsterdam, pp 1008-1055
2. Catalan VS, LeLorier J (2000) Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 3(6):417-426
3. Commissie Interacterende medicatie cumarines (2002) Standaard afhandeling cumarine-interacties [cited 2003 Feb 12]. Available from: URL: http://www.fnt.nl/artsen/index.html
4. Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30(6):416-444
5. Herings R (1993) PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands [dissertation]. Utrecht University, Department of Pharmaco-epidemiology and -therapy, Utrecht
6. Hermans JJ, Thijssen HH (1993) Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 110(1): 482-490
7. Holbrook AM, Wells PS, Crowther NR (1996) Pharmacokinetics and drug interactions with warfarin. In: Poller L, Hirsch J (eds) Oral anticoagulants. Arnold, London, pp 30-48
8. Indiana University Department of Medicine (2003) Cytochrome P450 Drug Interaction Table [cited 2003 Feb 12]. Available from: URL: http://medicine. iupui.edu/flockhart
9. Johnsen SP, Sorensen HT, Mellemkjoer L, Blot WJ, Nielsen GL, McLaughlin JK et al (2001) Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost 86(2):563-568
10. Labenz J, Petersen KU, Rosch W, Koelz HR (2003) A summary of food and drug administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 17(8):1015-1019
11. Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95(3):315-328
12. Li X-Q, Andersson TB, Ahlström M, Weidolf L (2004) Comparison of inhibitory effects of the proton pump inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32(8):821-827
13. Majerus PW, Tollefsen DM (2001) Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Goodman Gilman A, Limbird LE (eds) The pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York
14. McCarthy DM, McLaughlin TP, Griffis DL, Yazdani C (2003) Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. Am J Ther 10(5):330-340
15. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76(1):12-16
16. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348(9025):423-428
17. Penning-van Beest FJA, van Meegen E, Rosendaal FR, Stricker BHCh (2001) Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 69(6):451-457
18. Reynolds JEF (ed) (1999) Anticoagulants. Martindale: the extra pharmacopoeia, 32nd edn. The Pharmaceutical Press, London
19. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W et al (1996) Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 34(Suppl 1):S31-S50
20. Stockley IH (1996) Drug interactions, 4th edn. The Pharmaceutical Press, London
21. Visser LE, Penning-van Beest FJA, Kasbergen AA, De Smet PA, Vulto AG, Hofman A et al (2002) Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 71(6):496-502
22. Visser LE, Penning-van Beest FJA, Kasbergen AA, De Smet PA, Vulto AG, Hofman A et al (2002) Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 88(5):705-710
23. Visser LE, Penning-van Beest FJA, Wilson JH, Vulto AG, Kasbergen AA, De Smet PA et al (2004) Overanticoagulation associated with combined use of lactulose and coumarin anticoagulants. Br J Clin Pharmacol 57(4):522-524